Medicare News
New Medicare GLP-1 Bridge Program Starts July 1, 2026
A new Medicare program may help some people with Medicare access certain GLP-1 medications for weight
management beginning July 1, 2026.
The Centers for Medicare & Medicaid Services has announced the Medicare GLP-1 Bridge, a short-term
demonstration program designed to provide eligible Medicare Part D beneficiaries with access to certain
GLP-1 drugs. According to CMS, the program is scheduled to run from July 1, 2026, through December 31,
2027.
This is important Medicare news because GLP-1 medications have become a major topic for people managing
weight, diabetes, heart disease risk, sleep apnea, and other health-related conditions. However, the rules for
Medicare coverage can be confusing, and not every person with Medicare will qualify for the new Bridge
program
What Is the Medicare GLP-1 Bridge?
The Medicare GLP-1 Bridge is a short-term CMS demonstration program. It is intended to help certain
Medicare Part D beneficiaries access eligible GLP-1 drugs when the medication is prescribed for weight
management.
CMS explains that the Bridge operates outside the normal Medicare Part D benefit payment flow. That means
it is not the same as simply having the drug covered on your Medicare Part D plan formulary.
This is an important distinction. A person may have a Medicare Part D plan or a Medicare Advantage plan with
drug coverage, but the GLP-1 Bridge has its own eligibility rules, prior authorization process, and cost
structure.
When Does the Program Start?
The Medicare GLP-1 Bridge is scheduled to begin on July 1, 2026. CMS says prior authorization requests will
not be accepted or processed before July 1, 2026. More information about the prior authorization process is
expected before the program begins.
Which GLP-1 Drugs Are Included?
CMS currently lists the following eligible GLP-1 drugs for the Bridge program when used to reduce excess
body weight and maintain weight reduction:
• Foundayo®
• Wegovy®
• Zepbound® KwikPen®
CMS notes that all formulations of Foundayo®, all formulations of Wegovy®, and the KwikPen® formulation of
Zepbound® are included. The single-dose vial and single-dose pen formulations of Zepbound® are not
included under the Bridge program at this time.
Because CMS states this drug list may be updated during the program, people with Medicare should check
current information before assuming a specific drug or formulation is included.
What Will the Copay Be?
For eligible beneficiaries, CMS states that the copay will be $50 for GLP-1 drugs furnished under the Medicare
GLP-1 Bridge.
However, CMS also explains that these drugs are provided outside the regular Part D benefit payment flow.
That means:
• The Part D deductible does not apply.
• The $50 copay does not count toward true out-of-pocket costs under Part D.
• Low-Income Subsidy assistance does not apply to the Bridge copay.
This can be confusing because the person must generally be enrolled in an eligible Medicare Part D plan type,
but the Bridge itself is not handled like normal Part D drug coverage.
Who May Be Eligible?
The Medicare GLP-1 Bridge is not open to every person with Medicare. CMS says the program is nationwide
and available in all states and territories, but only eligible Medicare Part D beneficiaries who meet the Bridge
rules can use it.
In general, a person must be enrolled in an eligible Part D plan type, such as a standalone Medicare
prescription drug plan or a Medicare Advantage plan with prescription drug coverage. Certain other plan types
may also qualify, including Special Needs Plans, employer or union group waiver plans, and LI NET,
depending on the beneficiary’s situation.
What Clinical Criteria Apply?
CMS states that a provider must attest that the beneficiary meets the Bridge program’s clinical criteria.
The medication must be prescribed to reduce excess body weight and maintain weight reduction along with
ongoing lifestyle modification, including nutrition and physical activity consistent with the FDA-approved label.
CMS lists several possible clinical pathways, including:
• BMI of 35 or higher at the time GLP-1 therapy began; or
• BMI of 30 or higher with certain conditions such as heart failure with preserved ejection fraction,
uncontrolled hypertension, or chronic kidney disease stage 3a or above; or
• BMI of 27 or higher with certain conditions such as pre-diabetes, previous heart attack, previous stroke, or
symptomatic peripheral artery disease.
The details matter. A person’s provider will need to determine whether the person meets the medical criteria
and whether the drug is being prescribed for a Bridge-eligible use.
What If the GLP-1 Is Prescribed for Diabetes, Sleep Apnea, or Another Condition?
This is one of the most important points.
CMS states that the Medicare GLP-1 Bridge is designed for beneficiaries seeking GLP-1 drugs solely to
reduce excess body weight or maintain weight reduction
CMS also explains that GLP-1 drugs prescribed for certain other indications, such as Type 2 diabetes, obstructive sleep apnea, or noncirrhotic metabolic dysfunction-associated steatohepatitis, may be eligible for
regular Part D coverage instead. Beneficiaries with those diagnoses are generally expected to obtain their
GLP-1 medication through their Part D plan, not through the Bridge program.
That means people with Medicare should not assume the Bridge applies simply because they are taking or
considering a GLP-1 medication. The reason the medication is prescribed matters.
What Should People With Medicare Do Now?
At this time, CMS says beneficiaries do not need to register or opt in to access GLP-1 drugs through the
Medicare GLP-1 Bridge.
For now, people who are interested should:
• Talk with their medical provider about whether a GLP-1 medication is medically appropriate.
• Ask whether the medication would be prescribed for weight management or another medical condition.
• Review their current Medicare Part D or Medicare Advantage drug coverage.
• Watch for additional CMS guidance before July 1, 2026.
• Avoid sending personal medical information to CMS email addresses or unofficial sources.
Because this program involves medical criteria, prior authorization, drug formularies, and Medicare plan rules,
people should work with their provider and review their Medicare drug coverage carefully.
Why This Matters for Nevada Medicare Beneficiaries
For people with Medicare in Nevada, this new program may create an additional pathway to access certain
GLP-1 medications beginning July 1, 2026. However, it will not replace the need to review Medicare Part D
coverage, Medicare Advantage prescription drug coverage, formulary rules, prior authorization requirements,
and drug-specific coverage limitations.
The Medicare GLP-1 Bridge may help some eligible beneficiaries, but it is not automatic coverage and it is not
available for every diagnosis or every GLP-1 prescription.
Final Takeaway
The new Medicare GLP-1 Bridge is a significant Medicare development for 2026. It may provide eligible
Medicare Part D beneficiaries with access to certain GLP-1 medications for weight management at a $50
copay. But the program has specific eligibility rules, requires provider involvement, and operates outside the
normal Medicare Part D payment structure.
People with Medicare should check their current drug coverage, speak with their provider, and stay informed
as CMS releases more details before the July 1, 2026 start date.
To find out more Specifics about the Program and how a person can participate please visit the CMS.gov page regarding this ,
Heres is the Link:
www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge
This link will take you to CMS.gov where you can find out more Info
Medicare in Las Vegas can help you review your Medicare Part D or Medicare Advantage prescription
drug coverage and better understand how plan rules may apply to your medications.
The article above is written as a consumer-friendly Medicare News article and is based on CMS information
available as of June 4, 2026. Because CMS states that product lists and operational details may be updated
during the program, the article should be reviewed again before or near the July 1, 2026 launch date.
New Medicare GLP-1 Bridge Program Starts July 1, 2026
A new Medicare program may help some people with Medicare access certain GLP-1 medications for weight
management beginning July 1, 2026.
The Centers for Medicare & Medicaid Services has announced the Medicare GLP-1 Bridge, a short-term
demonstration program designed to provide eligible Medicare Part D beneficiaries with access to certain
GLP-1 drugs. According to CMS, the program is scheduled to run from July 1, 2026, through December 31,
2027.
This is important Medicare news because GLP-1 medications have become a major topic for people managing
weight, diabetes, heart disease risk, sleep apnea, and other health-related conditions. However, the rules for
Medicare coverage can be confusing, and not every person with Medicare will qualify for the new Bridge
program
What Is the Medicare GLP-1 Bridge?
The Medicare GLP-1 Bridge is a short-term CMS demonstration program. It is intended to help certain
Medicare Part D beneficiaries access eligible GLP-1 drugs when the medication is prescribed for weight
management.
CMS explains that the Bridge operates outside the normal Medicare Part D benefit payment flow. That means
it is not the same as simply having the drug covered on your Medicare Part D plan formulary.
This is an important distinction. A person may have a Medicare Part D plan or a Medicare Advantage plan with
drug coverage, but the GLP-1 Bridge has its own eligibility rules, prior authorization process, and cost
structure.
When Does the Program Start?
The Medicare GLP-1 Bridge is scheduled to begin on July 1, 2026. CMS says prior authorization requests will
not be accepted or processed before July 1, 2026. More information about the prior authorization process is
expected before the program begins.
Which GLP-1 Drugs Are Included?
CMS currently lists the following eligible GLP-1 drugs for the Bridge program when used to reduce excess
body weight and maintain weight reduction:
• Foundayo®
• Wegovy®
• Zepbound® KwikPen®
CMS notes that all formulations of Foundayo®, all formulations of Wegovy®, and the KwikPen® formulation of
Zepbound® are included. The single-dose vial and single-dose pen formulations of Zepbound® are not
included under the Bridge program at this time.
Because CMS states this drug list may be updated during the program, people with Medicare should check
current information before assuming a specific drug or formulation is included.
What Will the Copay Be?
For eligible beneficiaries, CMS states that the copay will be $50 for GLP-1 drugs furnished under the Medicare
GLP-1 Bridge.
However, CMS also explains that these drugs are provided outside the regular Part D benefit payment flow.
That means:
• The Part D deductible does not apply.
• The $50 copay does not count toward true out-of-pocket costs under Part D.
• Low-Income Subsidy assistance does not apply to the Bridge copay.
This can be confusing because the person must generally be enrolled in an eligible Medicare Part D plan type,
but the Bridge itself is not handled like normal Part D drug coverage.
Who May Be Eligible?
The Medicare GLP-1 Bridge is not open to every person with Medicare. CMS says the program is nationwide
and available in all states and territories, but only eligible Medicare Part D beneficiaries who meet the Bridge
rules can use it.
In general, a person must be enrolled in an eligible Part D plan type, such as a standalone Medicare
prescription drug plan or a Medicare Advantage plan with prescription drug coverage. Certain other plan types
may also qualify, including Special Needs Plans, employer or union group waiver plans, and LI NET,
depending on the beneficiary’s situation.
What Clinical Criteria Apply?
CMS states that a provider must attest that the beneficiary meets the Bridge program’s clinical criteria.
The medication must be prescribed to reduce excess body weight and maintain weight reduction along with
ongoing lifestyle modification, including nutrition and physical activity consistent with the FDA-approved label.
CMS lists several possible clinical pathways, including:
• BMI of 35 or higher at the time GLP-1 therapy began; or
• BMI of 30 or higher with certain conditions such as heart failure with preserved ejection fraction,
uncontrolled hypertension, or chronic kidney disease stage 3a or above; or
• BMI of 27 or higher with certain conditions such as pre-diabetes, previous heart attack, previous stroke, or
symptomatic peripheral artery disease.
The details matter. A person’s provider will need to determine whether the person meets the medical criteria
and whether the drug is being prescribed for a Bridge-eligible use.
What If the GLP-1 Is Prescribed for Diabetes, Sleep Apnea, or Another Condition?
This is one of the most important points.
CMS states that the Medicare GLP-1 Bridge is designed for beneficiaries seeking GLP-1 drugs solely to
reduce excess body weight or maintain weight reduction
CMS also explains that GLP-1 drugs prescribed for certain other indications, such as Type 2 diabetes, obstructive sleep apnea, or noncirrhotic metabolic dysfunction-associated steatohepatitis, may be eligible for
regular Part D coverage instead. Beneficiaries with those diagnoses are generally expected to obtain their
GLP-1 medication through their Part D plan, not through the Bridge program.
That means people with Medicare should not assume the Bridge applies simply because they are taking or
considering a GLP-1 medication. The reason the medication is prescribed matters.
What Should People With Medicare Do Now?
At this time, CMS says beneficiaries do not need to register or opt in to access GLP-1 drugs through the
Medicare GLP-1 Bridge.
For now, people who are interested should:
• Talk with their medical provider about whether a GLP-1 medication is medically appropriate.
• Ask whether the medication would be prescribed for weight management or another medical condition.
• Review their current Medicare Part D or Medicare Advantage drug coverage.
• Watch for additional CMS guidance before July 1, 2026.
• Avoid sending personal medical information to CMS email addresses or unofficial sources.
Because this program involves medical criteria, prior authorization, drug formularies, and Medicare plan rules,
people should work with their provider and review their Medicare drug coverage carefully.
Why This Matters for Nevada Medicare Beneficiaries
For people with Medicare in Nevada, this new program may create an additional pathway to access certain
GLP-1 medications beginning July 1, 2026. However, it will not replace the need to review Medicare Part D
coverage, Medicare Advantage prescription drug coverage, formulary rules, prior authorization requirements,
and drug-specific coverage limitations.
The Medicare GLP-1 Bridge may help some eligible beneficiaries, but it is not automatic coverage and it is not
available for every diagnosis or every GLP-1 prescription.
Final Takeaway
The new Medicare GLP-1 Bridge is a significant Medicare development for 2026. It may provide eligible
Medicare Part D beneficiaries with access to certain GLP-1 medications for weight management at a $50
copay. But the program has specific eligibility rules, requires provider involvement, and operates outside the
normal Medicare Part D payment structure.
People with Medicare should check their current drug coverage, speak with their provider, and stay informed
as CMS releases more details before the July 1, 2026 start date.
To find out more Specifics about the Program and how a person can participate please visit the CMS.gov page regarding this ,
Heres is the Link:
www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge
This link will take you to CMS.gov where you can find out more Info
Medicare in Las Vegas can help you review your Medicare Part D or Medicare Advantage prescription
drug coverage and better understand how plan rules may apply to your medications.
The article above is written as a consumer-friendly Medicare News article and is based on CMS information
available as of June 4, 2026. Because CMS states that product lists and operational details may be updated
during the program, the article should be reviewed again before or near the July 1, 2026 launch date.